21-09-2016 09:39 via seattletimes.com

Mylan CEO set to defend EpiPen prices amid public outcry

WASHINGTON (AP) — The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers. “Price and access exist in a balance, and we believe we have struck that balance,” Heather Bresch says in prepared testimony […]
Read more »